Turner, N. C., Alarcón, E., Armstrong, A. C., Philco, M., López Chuken, Y. A., Sablin, M. -., . . . Oliveira, M. (2019). BEECH: A dose-finding run-in followed by a randomised phase II study assessing the efficacy of AKT inhibitor capivasertib (AZD5363) combined with paclitaxel in patients with estrogen receptor-positive advanced or metastatic breast cancer, and in a PIK3CA mutant sub-population. Ann Oncol.
Citação norma ChicagoTurner, N C., et al. "BEECH: A Dose-finding Run-in Followed By a Randomised Phase II Study Assessing the Efficacy of AKT Inhibitor Capivasertib (AZD5363) Combined With Paclitaxel in Patients With Estrogen Receptor-positive Advanced or Metastatic Breast Cancer, and in a PIK3CA Mutant Sub-population." Ann Oncol 2019.
Citação norma MLATurner, N C., et al. "BEECH: A Dose-finding Run-in Followed By a Randomised Phase II Study Assessing the Efficacy of AKT Inhibitor Capivasertib (AZD5363) Combined With Paclitaxel in Patients With Estrogen Receptor-positive Advanced or Metastatic Breast Cancer, and in a PIK3CA Mutant Sub-population." Ann Oncol 2019.